COVID Infusion Center
Evusheld for Pre-exposure Prophylaxis - Evusheld (Tixagevimab/cilgavimab)(AstraZeneca) - has an EUA for pre-exposure prophylaxis against COVID-19. Read more about FDA Authorization of New Long Acting Monoclonal Antibodies Pre-exposure.
A combination of two long-acting anti-SARS-CoV-2 monoclonal antibodies administered via intramuscular injection, Evusheld is intended to protect individuals who are unable to mount an adequate immune response to COVID-19 vaccination or are unable to receive a COVID-19 vaccine due to severe adverse reaction. Read more about Evusheld.
Updated 01/24/22 - Note: Supplies are expected to be very limited. The California Department of Public Health is initially allocating product to Mutual Aid Regions with instructions to send treatment courses to transplant and cancer centers and other identified priority locations across their region.
Frequently Asked Questions
Who is eligible to receive Evusheld?
As defined in the EUA, Evusheld is authorized as a pre-exposure prophylaxis in the following:
Adults and pediatric individuals (12 years of age and older weighing at least 40 kg) and who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and either:
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination
or- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
According to the EUA, the medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:
- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200 /mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
- Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)
I’m a patient, how can I get the Evusheld Injection?
Your Eisenhower physician must use Epic to order an Ambulatory Referral to Evusheld Injection Clinic to expedite treatment. Alternatively, the provider may complete this referral form and fax to 760-773-2091.
Document
Prioritizing Evusheld administration – Guidance for Providers
Given the overall limited supply, the following resources will be used to aid in selecting patient prioritization for Evusheld:
- The CDC/IDSA Clinician Call on December 18, 2021 included patient prioritization tiers proposed by Duke Transplant/Immunocompromised Host Infectious Diseases Division. These tiers include prioritization of a variety of medical conditions and immunosuppressive therapies. Patients over the age of 65 receiving B-cell depleting therapies within the last 6 months are listed as the first priority tier.
- Additional guidance on patient prioritization can be found in the NIH COVID-19 Treatment Guidelines Panel’s Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints.
FDA: Letter of authorization | FAQs on the EUA | Fact sheet for health providers | Fact sheet for patient/caregivers
COVID-19 Prevention - Protect yourself and others
- Get a vaccine (read our Covid-19 FAQ)
- Physical distance
- More info from the CDC
